In a randomized trial, both 100-mg and 300-mg monthly maintenance doses of extended-release buprenorphine improved opioid abstinence in patients with high-risk opioid use, with no new safety signals.
Researchers conducted a case series study of 15 pregnant and postpartum patients with OUD treated with extended-release buprenorphine between January 1, 2023, and May 1, 2025, in an urban academic ...
Both monthly maintenance doses (100 mg and 300 mg) improved opioid abstinence and were well-tolerated with no new safety signals identified. Post-hoc analyses indicated the 300-mg monthly maintenance ...
Extended-release naltrexone gradually releases sufficient naltrexone to block the euphoric effects of opioids for approximately 1 month after injection and is efficacious as compared with placebo.
Extended-release buprenorphine (BUP-XR) had lower rates of hospitalizations, emergency department (ED) visits, and outpatient physician office visits compared to those receiving daily oral buprenorphine ...
The FDA released a draft of guidelines for the continuing education of prescribers of long-acting and extended release opioid drugs, according to a Medscape report. The blueprint, a basic outline and ...
MedPage Today on MSN
Novel Opioid Receptor Drug Cuts IPF Cough
Opioid agonist/antagonist has a big impact in phase IIb trial ...
Two dose levels of maintenance treatment with extended-release buprenorphine (Sublocade) improved opioid abstinence in patients with high-risk opioid use disorder (OUD), a randomized trial showed.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results